Dermira to Present at Stifel 2016 Healthcare Conference
09 nov. 2016 16h05 HE
|
Dermira, Inc.
MENLO PARK, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira Reports Third Quarter 2016 Financial Results and Provides Corporate Update
07 nov. 2016 16h07 HE
|
Dermira, Inc.
- Topline results for the first of three Phase 3 trials for CIMZIA® reported - DRM04 Phase 3 and DRM01 Phase 2b data presented at dermatology conferences - Acquired option to...
Dermira Presents Data from DRM01 Phase 2b Clinical Program at Annual Meeting for Dermatologists
21 oct. 2016 07h30 HE
|
Dermira, Inc.
MENLO PARK, Calif., Oct. 21, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira to Present Data from DRM01 and DRM04 Clinical Programs at Fall Clinical Dermatology Conference
13 oct. 2016 07h30 HE
|
Dermira, Inc.
MENLO PARK, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
03 oct. 2016 02h00 HE
|
Dermira, Inc.
BRUSSELS, Belgium and MENLO PARK, Calif., Oct. 03, 2016 (GLOBE NEWSWIRE) -- UCB (Euronext:UCB) and Dermira, Inc. (NASDAQ:DERM) today announced topline results from CIMPASI-2, a Phase 3,...
Dermira Presents Data from DRM04 Phase 3 Clinical Program in Late-Breaking News Session at European Academy of Dermatology and Venereology Congress
01 oct. 2016 03h05 HE
|
Dermira, Inc.
MENLO PARK, Calif., Oct. 01, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira Acquires Option to License Exclusive Rights for up to Three Early-Stage Programs from Takeda
12 sept. 2016 07h30 HE
|
Dermira, Inc.
MENLO PARK, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira Reports Second Quarter 2016 Financial Results and Provides Corporate Update
08 août 2016 16h12 HE
|
Dermira, Inc.
Reported Topline Results for Two Late-Stage Clinical ProgramsRaised Approximately $136 Million in Net Proceeds from Follow-on Public OfferingUpdates Guidance for Topline Phase 3 CIMZIA®...
Dermira Prices $126 Million Public Offering of Common Stock
08 juin 2016 07h00 HE
|
Dermira, Inc.
MENLO PARK, Calif., June 08, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira to Present Preclinical Data from DRM01 Acne Program at the Society for Investigative Dermatology 75th Annual Meeting
11 mai 2016 16h05 HE
|
Dermira, Inc.
MENLO PARK, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...